Seung-Hyun Jeon

Title: Seung-Hyun Jeon: Innovator in Cancer Treatment

Introduction

Seung-Hyun Jeon is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development of chimeric antigen receptors. His work focuses on creating targeted therapies for solid cancers, particularly in patients who have limited treatment options.

Latest Patents

Seung-Hyun Jeon holds a patent for a "Human anti-ANTXR chimeric antigen receptor and use thereof." This invention relates to a chimeric antigen receptor that specifically targets the anthrax toxin receptor (ANTXR). The patent includes a nucleic acid encoding a chimeric antigen receptor that comprises a ligand PA63, which binds specifically to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2). The invention also encompasses a vector containing this nucleic acid, a recombinant cell comprising the vector, and a pharmaceutical composition for preventing or treating solid cancer. This innovative approach allows for the treatment of solid cancers using an anti-ANTXR chimeric antigen receptor (CAR)-T cell, particularly benefiting patients with pancreatic cancer.

Career Highlights

Seung-Hyun Jeon is associated with Mjcell Bio Co., Ltd., where he continues to advance his research in cancer therapies. His work has the potential to revolutionize treatment options for patients suffering from solid tumors, providing customized and effective solutions.

Collaborations

Seung-Hyun Jeon collaborates with notable colleagues, including Kyung-Mi Lee and Baeckseung Lee. Their combined expertise contributes to the innovative research and development efforts at Mjcell Bio Co., Ltd.

Conclusion

Seung-Hyun Jeon's contributions to the field of cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work in developing targeted therapies showcases the potential for advancements in medical science.